8-K
Current Report
Candel Therapeutics, Inc. Filed Acc 0000950170-23-066248
Exit or restructuring costs
- Item 2.05 Costs associated with exit or disposal activities
From the SEC's structured data for this filing
Loading cadl-20231126.htm…